Protein lysine lactic acid acylation detection reagent and application
By developing affinity reagents that specifically bind lactic acid acylated lysine in peptides, the problem of post-translational modification of histones or non-histones is solved, and the diagnosis of Waberg effect-related diseases is achieved and histone lactic acid acyl has been achieved. The study of chemistry in gene expression regulation provides an in-depth understanding of lactic acid function.
Patent Information
- Application Number
- CN202410986053.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-12-21
- Filing Date
- 2019-12-19
- Publication Date
- 2024-12-06
AI Technical Summary
Existing detection techniques are difficult to effectively detect post-translational modifications of histones or non-histones associated with various diseases, especially lactic acid acylated lysine, limiting the in-depth understanding and diagnosis of Waberg effect and related diseases.
Affinity reagents and methods specifically bind to lactic acid acylated lysine in peptides were developed, using these reagents to specifically bind to lactic acid acylated lysine in peptides to detect and isolate proteins. Or lysine lactic acid acylated in its fragments provides a tool for detection and diagnosis.
Through these reagents and methods, lysine lactic acid acylated in proteins or fragments can be accurately detected, providing diagnostic means for the Waberg effect and related diseases, and revealing the regulation of histone lactic acid acylation in gene expression The role of filling the gap in knowledge of lactic acid in physiology and pathology.
Smart Images

Figure CN119080940A_ABST
Abstract
Description
[0001] This application is a divisional application of a prior application in China, application number: 2019800879999, and application date: December 19, 2019.
[0002] Citation to Related Applications
[0003] This patent application claims priority to U.S. Provisional Patent Application No. 62 / 783926, filed on December 21, 2018, the entire contents of which are incorporated herein by reference for all purposes.
[0004] Citations Supported by the U.S. Government
[0005] This work was supported by the National Institutes of Health (NIH) under grant number DK107868. The United States has certain rights to this invention. Field of the Invention
[0006] The present invention relates to a reagent and method for detecting proteins with post-translational modifications, and in particular to a peptide constituting lactic acid acylated lysine, and its use in developing a reagent and method for detecting protein lysine lactic acid acylation. Background of the Invention
[0007] The Warburg effect (originally used to describe increased lactate production in cancer) has been linked to a variety of cellular processes, such as angiogenesis, hypoxia, macrophage polarization, and T-cell activation. This phenomenon is closely related to a variety of diseases, such as tumors, sepsis, and autoimmune diseases. Lactate is one of the compounds produced during the Warburg effect. It is well known as an energy source and metabolic byproduct. However, its role in non-metabolic functional physiology and disease is not well understood.
[0008] Therefore, there is still a need to develop reagents and methods for detecting post-translational modifications of histone or non-histone proteins associated with various diseases and symptoms. SUMMARY OF THE INVENTION
[0009] The present invention relates to an affinity reagent for specifically binding to lactic acid acylated lysine in a peptide, and its preparation and use. The invention is based on a novel histone mark discovered by the inventor: lactic acid acylation of lysine.
[0010] The present invention provides an isolated affinity agent that can specifically bind to lactic acid acylated lysine in a peptide. The peptide can be derived from a histone or a fragment thereof. The histone can be obtained from an organism selected from humans, mice, saccharomyces cerevisiae, thermophilic Tetrahymena, Drosophila melanogaster and Caenorhabditis elegans. The peptide can contain an amino acid sequence selected from sequence numbers: 29-87, and the sequence must have a homology of more than 70% with the amino acid sequence. The peptide can contain an amino acid sequence selected from sequence numbers: 29-87, and the peptide can contain at least one or two amino acid residues on each N-terminal and C-terminal side of the lactic acid acylated lysine. The binding of the affinity agent to the peptide can depend on the surrounding peptide sequence of the lactic acid acylated lysine in the peptide. The affinity agent can be a protein or an antibody.
[0011] The present invention provides a method for detecting lactic acid acylated lysine in a protein or a fragment thereof. The method comprises contacting the protein or the fragment thereof with an affinity reagent, wherein the affinity reagent can specifically bind to the lactic acid acylated lysine in the peptide, thereby forming a binding complex of the protein or the fragment thereof and the affinity reagent; at the same time, by detecting the binding complex, it can be concluded that the presence of the binding complex indicates the presence of lactic acid acylated lysine in the protein or the fragment thereof. The detection method may further comprise quantifying the lactic acid acylated lysine in the protein or the fragment thereof.
[0012] According to the detection method, the peptide is derived from histone or a fragment thereof. The histone can be obtained from an organism selected from humans, mice, Saccharomyces cerevisiae, Tetrahymena thermophila, Drosophila melanogaster and Caenorhabditis elegans. The peptide can contain an amino acid sequence selected from sequence numbers: 29-87, and the sequence must have a homology of more than 70% with the amino acid sequence. The peptide can contain an amino acid sequence selected from sequence numbers: 29-87, and the peptide can contain at least one or two amino acid residues on each N-terminal and C-terminal side of the lactic acid acylated lysine. The binding of the affinity reagent to the peptide can depend on the surrounding peptide sequence of the lactic acid acylated lysine in the peptide. The affinity reagent can be a protein or an antibody.
[0013] The present invention provides a first method for separating an affinity reagent that specifically binds to lactacylated lysine in a peptide. The method is to expose a protein library to a peptide containing lactacylated lysine, so that the protein from the protein library can specifically bind to the lactacylated lysine and form a binding complex with the peptide; at the same time, the protein can be separated from the binding complex, and the separated protein is the affinity reagent. The peptide can contain at least one or two amino acid residues on each N-terminal and C-terminal side of the lactacylated lysine.
[0014] The present invention also provides a second method for isolating an affinity reagent that specifically binds to lactylated lysine in a peptide. The method comprises immunizing a host with a peptide containing lactylated lysine, thereby causing the host to produce antibodies; then isolating the antibodies from the host, and the isolated antibodies are the affinity reagent. The peptide may contain at least one or two amino acid residues on each of the N-terminal and C-terminal sides of the lactylated lysine.
[0015] The first kit provided by the present invention comprises an affinity reagent that specifically binds to lactic acid acylated lysine in a peptide, and instructions for using the affinity reagent to detect lactic acid acylated lysine in a protein or a fragment thereof according to the detection method provided by the present invention.
[0016] The second kit provided by the present invention comprises a peptide containing lactylated lysine and instructions for isolating an affinity reagent that specifically binds to lactylated lysine in the peptide according to the first or second separation method of the present invention.
[0017] The present invention provides an isolated peptide containing lactic acid acylated lysine. The peptide is derived from histones or fragments thereof. The histones can be obtained from organisms selected from humans, mice, saccharomyces cerevisiae, thermophilic Tetrahymena, Drosophila melanogaster and Caenorhabditis elegans. The peptide can contain an amino acid sequence selected from sequence numbers: 29-87, and the sequence must have a homology of more than 70% with the amino acid sequence. The peptide can contain an amino acid sequence selected from sequence numbers: 29-87, and the peptide can contain at least one or two amino acid residues on each N-terminal and C-terminal side of the lactic acid acylated lysine.
[0018] BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 The identification and validation of histone Kla are shown. A. Schematic diagram of Kla structure. b is the MS / MS mass spectrum of lactic acid acylated histone peptide (H3K23la) from MCF-7 cells (in vivo) and its synthetic counterpart and mixture. bi refers to the amino terminal ion of the peptide and yi refers to the carboxyl terminal ion of the peptide. The data in the figure represent two independent replicates. c is a schematic diagram of the histone Kla site tested in human and mouse cells.
[0020] Figure 2Figure 4 shows the regulation of histone Kla by lactate. Data in the figure show the levels of lactate (a, d) and histone Kla (b) in MCF-7 cells after treatment with different concentrations of glucose and 2-DG for 24 h. A lactate colorimetric kit was used to measure lactate; N = 3 biological replicates; statistical significance was determined by one-way ANOVA and Sidak's multiple comparison test. Histone samples extracted with acid were subjected to immunoblotting. Pan anti-Kla and anti-Kac immunoblots showed molecular weights between 10 kD and 15 kD. e shows the regulation of glycolysis and lactate production by various metabolic regulators. f shows the intracellular lactate levels measured after treatment of MCF-7 cells with the indicated glycolysis regulators for 24 h. N = 3 biological replicates; statistical significance was determined by one-way ANOVA and Dunnett's multiple comparison test. gi shows the immunoblotting reactions of acid-extracted histones (rotenone and DCA) or whole cell lysates (oxamate) of MCF-7 cells with different glycolysis regulators. j is the measurement of intracellular lactate levels in MCF-7 cells under hypoxia. N = 4 biological replicates; statistical significance was determined using an unpaired t-test (two-tailed). k is an acid-extracted histone immunoblot of MCF-7 cells under hypoxia (1% oxygen). Values in panels a, d, f, and j are presented as means and their standard errors. Data in panels b, g, h, i, and k are from three independent replicates.
[0021] Figure 3The correlation between the increase of histone Kla and the activation of M2-like genes during M1 macrophage polarization is shown. ac are LPS+IFNγ activated bone marrow-derived macrophages (BMDMs). Intracellular lactate was measured using a lactate colorimetric kit (a). N = 3 biological replicates; statistical significance was determined using one-way ANOVA and Dunnett's multiple comparison test. Histone acylation was analyzed by immunoblotting using whole cell lysates (b, c). ImageJ was used for quantification; n = 3 technical replicates. The data in the figure represent two independent replicates. d is the result of BMDM cells stimulated with PBS (M0), LPS+IFNγ (M1), and interleukin-4 (M2) for 24 hours, respectively. Acid-extracted histones were used for immunoblotting. e, f are scatter plots (e) and bar graphs (f) showing gene promoters marked by H3K18la (H3K18la-log2[M1 / M0]≥1 and H3K18ac-log2[M1 / M0]≤0.5, H3K18la-specific), elevated in both H3K18la and H3K18ac (H3K18la-log2[M1 / M0]≥1 and H3K18ac-log2[M1 / M0]≥0.5, shared), or exclusively elevated H3K18ac (H3K18ac-log2[M1 / M0]≥1 and H3K18la-log2[M1 / M0]≤0.5, H3K18ac-specific). g, h Heatmaps showing gene expression dynamics of typical inflammatory genes (g) and H3K18la-specific genes (h) using per kilobase of transcript per million sequenced fragments (RPKM) values from RNA-seq. The color key indicates the log2-transformed fold change relative to gene expression at 0 h. N = 4 biological replicates. In i, j, BMDM cells were infected with Gram-negative bacteria or LPS, respectively. Histone Kla levels were measured by immunoblotting (i) 24 h after bacterial challenge. “+” indicates low dose and “++” indicates high dose. Gene expression at the indicated time points after bacterial challenge was analyzed by RT-qPCR (j). N = 3 biological replicates. k is the protein levels of inducible nitric oxide synthase (iNOS) and arginine 1 (ARG1) detected by immunoblotting. Values in panels a, b, c, and j are presented as means and their standard errors, and the data in the figures represent three independent replicates.
[0022] Figure 4Figure 2 shows that lactate activates gene expression of the M2 class via histone Kla. ad indicates that when LDHA is deficient (myeloid-specific LDHA- / -), the reduction in lactate secretion by BMDM cells leads to a decrease in histone Kla levels and Arg1 expression during M1 polarization. Intracellular lactate levels were measured using a lactate colorimetric kit (a), and histone Kla levels were measured by immunoblotting (b) 24 hours after M1 polarization. c is gene expression analyzed by RT-qPCR at the indicated time points after M1 polarization. ac, N=3 biological replicates. d is the occupancy of H3K18la analyzed by ChIP-qPCR 24 hours after M1 polarization. Data represent three technical replicates from mixed samples. eh is exogenous lactate (25 mM) added to BMDM cells 4 hours after M1 polarization (LPS+IFNγ), and cells were collected at the indicated time points after M1 polarization for intracellular lactate measurement (e), histone Kla immunoblot analysis (f), gene expression analysis (g), and H3K18la occupancy analyzed by ChIP-qPC (h). e, N = 3 biological replicates, f, data in the figure represent 3 different experiments. g, RPKM: per kilobase of transcript per million sequenced fragments (RPKM). N = 4 biological replicates. h, data represent three technical replicates from the mixed sample. Values in panels a, c, d, e, g, and h are presented as means and their standard errors; statistical significance was determined by multiple t-tests corrected by the Holm-Sidak method (a, c, e, and g).
[0023] Detailed description of the invention
[0024] The present invention relates to isolated peptides of lactic acid acylated lysine, affinity reagents that specifically bind to lactic acid acylated lysine in peptides, and their preparation and use. The present invention is based on the inventors' discovery of lactic acid-derived histone lysine lactic acid acylation, which can be used as a new epigenetic modification and prove that histone lactic acid acylation directly stimulates gene transcription from chromatin. The inventors have identified 28 lactic acid acylation sites on core histones in human and mouse cells. Hypoxia and bacterial challenge induce lactic acid production through glycolysis, which in turn is a precursor to stimulate histone lactic acid acylation. Using M1 macrophages exposed to bacteria as a model system, the inventors found that histone lactic acid acylation has different temporal dynamics from acetylation. In the late stage of M1 macrophage polarization, the lactic acid acylation modification of histones is enhanced, thereby inducing homeostatic genes involved in wound healing, including arginase 1. Overall, these results indicate that the endogenous "lactate clock" in bacterially attacked M1 macrophages turns on gene expression to promote homeostasis. Therefore, histone lactate acylation provides an opportunity to improve the understanding of the function of lactate and its role in various pathophysiological conditions, including infection and cancer.
[0025] The term "peptide" as used herein refers to a linear chain of two or more amino acids connected by peptide bonds. A peptide may contain about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, 100, 200 or more amino acids. The amino acids of a peptide may be modified, deleted, added or substituted. Peptides may be obtained using conventional techniques known in the art, for example, synthesized or obtained from natural or recombinant proteins by enzymatic digestion.
[0026] As used herein, the term "polypeptide" refers to a peptide having at least four amino acids, preferably more than about 20 amino acids, without regard to post-translational modifications. As used herein, the term "protein" refers to a biological molecule composed of one or more polypeptides, without regard to post-translational modifications. Each polypeptide in a protein can be a subunit. Polypeptides or proteins can be in native or modified form and can exhibit biological functions or properties.
[0027] If the protein is a single polypeptide, the terms "protein" and "polypeptide" are used interchangeably herein. A fragment of a polypeptide or protein refers to a portion of the polypeptide or protein, and its amino acid sequence is identical to a portion (but not all) of the amino acid sequence of the polypeptide or protein. It is better if the fragment of a polypeptide or protein exhibits the same or similar biological function or characteristics as the polypeptide or protein.
[0028] As used herein, the term "derived from" refers to the source or origin from which a biomolecule is obtained, and may include naturally occurring, recombinant, unpurified or purified molecules. Biomolecules such as peptides (e.g., polypeptides or proteins) may be derived from an original molecule and may become identical to the original molecule or a variant of the original molecule. For example, a peptide derived from an original peptide may have an amino acid sequence that is identical or similar to the amino acid sequence of its original peptide, and at least one amino acid has been modified, deleted, inserted or substituted. A derivative peptide may have at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99% or 100% of the amino acid sequence, preferably at least about 50%, more preferably at least about 80%, and most preferably at least about 90%, and it is identical to the amino acid sequence of its original peptide, without taking into account post-translational modifications. It is even better if the derived biomolecule (e.g., peptide) can exhibit the same or similar biological functions or characteristics as the original biomolecule.
[0029] The term "antibody" used herein includes whole antibodies, antigen-binding fragments (or antigen-binding portions) and single chains thereof. A complete antibody can be any of two types. The first type refers to a glycoprotein that usually has two heavy chains and two light chains, and includes an antigen-binding portion. For example, an antibody can be a polyclonal or monoclonal antibody. The term "antigen-binding portion" used herein with respect to antibodies refers to one or more fragments of an antibody that retains the ability to specifically bind to an antigen. The second type is a heavy chain antibody in camels, also known as a nanobody. The term "single-chain variable region fragment" used herein with respect to antibodies refers to a fusion protein of the variable regions of the heavy and light chains of an antibody, which can be connected to a short connecting peptide of, for example, about 20-25 amino acids, and can retain the ability to specifically bind to an antigen.
[0030] The present invention provides an isolated peptide comprising lactic acid acylated lysine. The term "lactylated lysine" as used herein refers to a lysine residue modified by an L-lactic acid group. The term "lysine lactylated site" as used herein refers to a lysine residue in a peptide, polypeptide or protein that can be lactic acid acylated on the epsilon amino group of the lysine residue. The term "lysine lactylated" as used herein refers to lactic acid acylation on the epsilon amino group of a lysine residue that produces lactylated lysine.
[0031] The peptides of the present invention may have at least about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150 or 200 amino acids. The peptides may have about 3-25 amino acids, preferably 5-20 amino acids, and more preferably 6-14 amino acids.
[0032] The peptides of the present invention can be obtained using conventional techniques known in the art. The peptides can be derived from proteins having lysine lactic acid acylation sites, such as histones or fragments thereof. Histones can be derived from eukaryotic cells. Examples of eukaryotic cells include cells from yeast (e.g., Saccharomyces cerevisiae), Caenorhabditis elegans, fruit flies (Drosophila melanogaster (S2)), Tetrahymena (e.g., Thermohymena thermophila), mice (e.g., Mus musculus (MEF)) or humans. Preferably, the eukaryotic cells are mammalian cells, derived from cells of humans, primates, mice, rats, horses, cattle, pigs, sheep, goats, chickens, dogs or cats. More preferably, the eukaryotic cells are human cells.
[0033] Histone can be a histone linker or a histone core protein. Histone linker can be selected from the H1 family, including the H1F subfamily (e.g., H1F0, H1FNT, H1FOO, and H1FX) and the H1H1 subfamily (e.g., HIST1H1A, HIST1H1B, HIST1H1C, HIST1H1D, HIST1H1E, and HIST1H1T). Histone core protein can be a member of the H2A, H2B, H3, or H4 family. The histone core protein in the H2A family can be a member of the H2AF subfamily (e.g., H2AFB1, H2AFB2, H2AFB3, H2AFJ, H2AFV, H2AFX, H2AFY, H2AFY2 and H2AFZ), the H2A1 subfamily (e.g., HIST1H2AA, HIST1H2AB, HIST1H2AC, HIST1H2AD, HIST1H2AE, HIST1H2AG, HIST1H2AH, HIST1H2AI, HIST1H2AJ, HIST1H2AK, HIST1H2AL and HIST1H2AM) or the H2A2 subfamily (e.g., HIST2H2AA3, HIST2H2AA4, HIST2H2AB and HIST2H2AC). The histone core protein in the H2B family can be a member of the H2BF subfamily (e.g., H2BFM and H2BFWT), the H2B1 subfamily (e.g., HIST1H2BA, HIST1H2BB, HIST1H2BC, HIST1H2BD, HIST1H2BE, HIST1H2BF, HIST1H2BG, HIST1H2BH, HIST1H2BI, HIST1H2BJ, HIST1H2BK, HIST1H2BL, HIST1H2BM, HIST1H2BN and HIST1H2BO), or the H2B2 subfamily (e.g., HIST2H2BE and HIST2H2BF). The histone core protein in the H3 family can be a member of the H3A1 subfamily (e.g., HIST1H3A, HIST1H3B, HIST1H3C, HIST1H3D, HIST1H3E, HIST1H3F, HIST1H3G, HIST1H3H, HIST1H3I and HIST1H3J), the H3A2 subfamily (e.g., HIST2H3A, HIST2H3C and HIST2H3D) or the H3A3 subfamily (e.g., HIST3H3), the H3A3 subfamily (e.g., H3F3A, H3F3B and H3F3C).The histone core protein in the H4 family can be a member of the H41 subfamily (e.g., HIST1H4A, HIST1H4B, HIST1H4C, HIST1H4D, HIST1H4E, HIST1H4F, HIST1H4G, HIST1H4H, HIST1H4I, HIST1H4J, HIST1H4K, and HIST1H4L) or the H44 subfamily (e.g., HIST4H4).
[0034] The protein and gene sequences of histones of various species in the present invention are known in the art. For example, the histone sequences of humans, mice, Saccharomyces cerevisiae, Tetrahymena, Drosophila melanogaster and Caenorhabditis elegans can be found in the GenBank database Accession Nos. P16403 (H12 human) (sequence number: 1), P0C0S8 (H2A1 human) (sequence number: 2), P62807 (H2B1C human) (sequence number: 3), P84243 (H33 human) (sequence number: 4) and P62805 (H4 human) (sequence number: 5); P15864 (H1 2 mouse) (SEQ ID NO: 6), P22752 (H2A1 mouse) (SEQ ID NO: 7), P10853 (H2B1F mouse) (SEQ ID NO: 8), P84244 (H33 mouse) (SEQ ID NO: 9) and P62806 (H4 mouse) (SEQ ID NO: 10); P04911 (H2A1 Saccharomyces cerevisiae) (SEQ ID NO: 11), P02294 (H2B2 Saccharomyces cerevisiae) (SEQ ID NO: 12), P61830 (H3 Saccharomyces cerevisiae) (SEQ ID NO: 13) and P02309 ( H4 Saccharomyces cerevisiae) (SEQ ID NO: 14); P35065 (H2A1 Tetrahymena thermophila) (SEQ ID NO: 15), P08993 (H2B1 Tetrahymena thermophila) (SEQ ID NO: 16), I7LUZ3 (H3 Tetrahymena thermophila) (SEQ ID NO: 17) and P69152 (H4 Tetrahymena thermophila) (SEQ ID NO: 18); P02255 (H1 Drosophila melanogaster) (SEQ ID NO: 19), P08985 (H2AV Drosophila melanogaster) (SEQ ID NO: 20), P02283 (H2B Drosophila melanogaster) (SEQ ID NO: 21), P02299 (H3) (SEQ ID NO: 22) and P84040 (H4 Drosophila melanogaster) (SEQ ID NO: 23); P10771 (H11 Caenorhabditis elegans) (SEQ ID NO: 24), P09855 (H2A Caenorhabditis elegans) (SEQ ID NO: 25), P04255 (H2B1 Caenorhabditis elegans) (SEQ ID NO: 26), P08898 (H3 Caenorhabditis elegans) (SEQ ID NO: 27) and P62784 (H4 Caenorhabditis elegans) (SEQ ID NO: 28).
[0035] The histone fragment may have an amino acid sequence identical to a portion (but not all) of the histone amino acid sequence comprising at least one lysine lactic acid acylation site. The histone fragment may have at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150 or 200 amino acids. The histone fragment may have about 3-25 consecutive amino acids of the histone, preferably about 5-20 consecutive amino acids, and more preferably about 6-14 consecutive amino acids, and the histone should cover at least one lysine lactic acid acylation site in the histone. The lactic acid acylation site may or may not have been lactic acid acylated. Table 1 provides peptides comprising lactic acid acylated lysine.
[0036] Table 1. Peptides containing lactic acid acylated lysine (Kla)
[0037]
[0038]
[0039] The peptide can be an antigenic peptide or a decoy peptide. The antigenic peptide or decoy peptide can include the five residue sequences shown in the left column of Table 1, or can include four consecutive residues of any one of the five residue sequences shown in Table 1, or at least six consecutive residues of any one of the nine residue sequences shown in Table 1.
[0040] Histones can be obtained from biological samples or prepared using recombinant techniques. Histone fragments can be prepared by recombinant techniques or by digestion of histones by enzymes (e.g., trypsin). Lysine lactic acid acylation sites in histones or fragments can be natural or artificial. The presence of lactic acid acylated lysine can be confirmed by using conventional techniques known in the art (e.g., mass spectrometry).
[0041] The peptide of the present invention may comprise an amino acid sequence similar to the amino acid sequence shown in Table 1, with a similarity of at least about 70%, 80%, 90%, 95% or 99%, preferably at least about 90%, and more preferably 100%. The peptide may comprise any lactic acid acylated lysine site, and may or may not comprise its surrounding sequence from histone. At the same time, the peptide may comprise more than one lactic acid acylated lysine, and may also comprise protein post-translational modifications other than lysine lactic acid acylation, such as lysine acetylation or methylation. The peptide may further comprise at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more residues, which residues must be located at either or both ends of the N-terminal and C-terminal sides of the lactic acid acylated lysine. The peptide may comprise at least one or two amino acid residues on each N-terminal and C-terminal side of the lactic acid acylated lysine. The peptide segments of the present invention are shown in Table 1.
[0042] The present invention also provides an affinity reagent for separation. The affinity reagent can specifically bind to the lactic acid acylated lysine in a peptide, polypeptide or protein. Therefore, the affinity reagent is also referred to as a lysine lactic acid acylated specific affinity reagent. Wherein, the peptide can be derived from a histone or a fragment thereof, and the affinity reagent can be a protein, for example, an antibody. The lysine lactic acid acylation site can be any lysine lactic acid acylation site in any histone from any species. The lactic acid acylated lysine can be any lactic acid acylated lysine in any histone from any species. Examples of lysine lactic acid acylation sites or lactic acid acylated lysines include the examples shown in Table 1, as well as homologous lysine sites in other corresponding eukaryotic histones.
[0043] In some embodiments, the affinity agent has a binding affinity for lysine in a peptide, polypeptide, or protein that is at least about 10, 50, 100, 500, 1000, or 5000 times greater when the lysine is acylated with lactic acid than when the lysine is not acylated with lactic acid.
[0044] In some other embodiments, the affinity agent has a binding affinity for lysine in a peptide, polypeptide, or protein when the lysine is not lactate-acylated that is at least about 10, 50, 100, 500, 1000, or 5000 times greater than the binding affinity for lysine in a peptide, polypeptide, or protein when the lysine is lactate-acylated.
[0045] The affinity agent can be a peptide, polypeptide or protein, or an antibody. The peptide is preferably a peptide containing lactic acid acylated lysine in the present invention.
[0046] In some embodiments, the binding of affinity reagents to lactic acid acylated lysine in peptides, polypeptides or proteins depends on the surrounding peptide sequence of lactic acid acylated lysine. The surrounding peptide sequence may contain at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more residues, and it should be located at either or both ends of the N-terminal and C-terminal sides of the lactic acid acylated lysine. For example, the binding may depend on at least one or two amino acid residues on the N-terminal side and / or the C-terminal side of the lactic acid acylated lysine.
[0047] In some other embodiments, the binding of the affinity agent to the lactylated lysine in the peptide, polypeptide or protein is independent of the surrounding peptide sequence of the lactylated lysine. For example, the affinity agent can be an anti-lactylated lysine pan-antibody.
[0048] The present invention also provides a method for separating an affinity reagent, wherein the affinity reagent can specifically bind to lactic acid acylated lysine in a peptide, polypeptide or protein.
[0049] When the affinity agent is a protein, the separation method may include exposing a protein library (also referred to as a display library or a degenerate protein library) to a peptide containing lactic acid acylated lysine, so that the protein from the protein library specifically binds to the lactic acid acylated lysine and forms a binding complex with the peptide, polypeptide or protein. The method may also separate the protein from the binding complex. The separated protein is the affinity agent.
[0050] The protein library may contain many degenerate protein sequences, which may contain two regions: one or more fixed peptide sequence regions and a plurality of degenerate amino acid sequences. The protein library may be a phage protein library, a yeast protein library, a bacterial protein library, a ribosomal protein library or other synthetic protein libraries containing peptides with random amino acid sequences.
[0051] If the affinity agent is an antibody, it can be isolated by various methods known in the art. For example, the isolation method may include immunizing a host with a peptide, polypeptide or protein containing lactic acid acylated lysine, thereby causing it to produce antibodies, and then further isolating the antibodies from the host. Therefore, the isolated antibodies are the affinity agent.
[0052] The host can be a mammal suitable for producing antibodies, for example, mice, rabbits, goats, camelids (such as alpacas and camels) or cartilaginous fish. Due to the different selection of hosts, the antibodies produced may contain two chains (heavy chain and light chain) or one chain called nanobody (only heavy chain antibodies in camelids).
[0053] In the separation method, the peptide, polypeptide or protein may have at least two, three, four or five amino acid residues on the N-terminal side and / or the C-terminal side of the lactacylated lysine.
[0054] In the separation method, the peptide, polypeptide or protein can be derived from a histone or a fragment thereof containing a lysine lactate acylation site, and can be lactate acylated or not, but preferably lactate acylated.
[0055] Examples of peptides having lactic acid acylated lysine may include one or more of the peptides shown in Table 1. Examples of peptides not having lactic acid acylated lysine may include the same amino acid sequences as those shown in Table 1, but the lysine lactic acid acylation site should not be lactic acid acylated. The N-terminus or C-terminus of these peptides may extend by 1-20 residues.
[0056] The separation method further comprises purifying the antibody from the host's antiserum, or using spleen cells from the host to produce monoclonal antibodies. In some embodiments, the antibody specifically binds to a histone or fragment having a lysine lactic acid acylation site when the site is lactic acid acylated, but does not bind when the site is not lactic acid acylated. In some other embodiments, the antibody specifically binds to a histone or fragment having a lysine lactic acid acylation site when the site is not lactic acid acylated, but does not bind when the site is lactic acid acylated.
[0057] The method may further include deriving the antibody sequence by high performance liquid chromatography (HPLC)-mass spectrometry analysis of the separated antibody, and then searching the protein sequence database for all possible IgG protein sequences (derived from cDNA sequences) from the bone marrow (or B cells) of the immune host. The IgG cDNA sequence can be obtained by conventional DNA sequencing technology means of the IgG cDNA produced by RT-PCR using known techniques. The derived heavy chain and light chain variable regions (VH and VL) can be further paired (if the IgG is a double-chain antibody from a host such as a mouse or rabbit). Such pairing does not need to be performed in IgG of pure heavy chain antibodies (or non-antibodies) derived from alpacas. Antibodies can be generated using antibody sequence information using known technical means.
[0058] The present invention provides a method for detecting lactic acid acylated lysine in a protein or a fragment thereof. The detection method comprises (a) contacting a protein or a fragment thereof with an affinity reagent of the present invention to form a binding complex of the protein or its fragment and the affinity reagent, and (b) detecting the binding complex. And the protein may be a histone. The affinity reagent may specifically bind to the lactic acid acylated lysine in the peptide of the present invention. The presence of the binding complex indicates the presence of lactic acid acylated lysine in the protein or its fragment. The binding complex may also be detected by using various conventional methods in the art. The method further comprises quantifying lactic acid acylated lysine in the protein or its fragment. The amount of the binding complex may indicate the amount of lactic acid acylated lysine in the protein or its fragment.
[0059] Each detection method in the present invention provides a kit, which contains an affinity reagent that specifically binds to lactic acid acylated lysine in a peptide, and also includes instructions for using the affinity reagent according to the detection method provided by the present invention to detect lactic acid acylated lysine in a protein or a fragment thereof.
[0060] Each separation method in the present invention provides a kit. The kit includes a peptide containing lactic acid acylated lysine. The kit also includes instructions for separation affinity reagents, and the affinity reagents can specifically bind to lactic acid acylated lysine in the peptide according to the separation method of the present invention.
[0061] The present invention provides a fusion protein reporter gene. The fusion protein reporter gene comprises a core flanked by a donor fluorescent moiety and an acceptor fluorescent moiety. The core comprises a peptide, and the peptide comprises a lysine lactic acid acylation site and a lysine lactic acid acylation binding domain. The term "lysine lactic acid acylation binding domain" as used herein refers to a region in a protein sequence that can specifically bind to a lysine lactic acid acylation binding site, which may or may not be lactic acid acylated.
[0062] The fusion protein reporter gene in the present invention can be used to measure the protein lysine lactic acid acylation level in the sample or to screen the reagent that can regulate protein lysine lactic acid acylation by using fluorescence resonance energy transfer (FRET). When the fluorophores are close, FRET will involve the transfer of photon energy between the fluorophores. In the art, it is known that the donor fluorescent moiety and the acceptor fluorescent moiety are suitable for FRET. In the fusion protein reporter gene, the donor fluorescent moiety can be selected from the group consisting of cyan fluorescent protein (CFP), enhanced cyan fluorescent protein (ECFP) and A206K mutants thereof, and the acceptor fluorescent moiety can be selected from the group consisting of yellow fluorescent protein (YFP), enhanced yellow fluorescent protein (EYFP), Citrine, Venus and A206K mutants thereof.
[0063] The peptide in the fusion protein reporter gene may include the peptide of the present invention, which may be derived from a histone or fragment comprising a lysine lactic acid acylation site, and the histone or fragment may be lactic acid acylated at the lysine lactic acid acylation site or may not be lactic acid acylated.
[0064] The lysine lactic acid acylation site can be located at the N-terminal, C-terminal or core region of the histone. In the art, the N-terminal, C-terminal and core regions of histones (e.g., human or mouse H1.2, H2A, H2B, H3 or H4) are known.
[0065] The fusion protein reporter gene may comprise one or more lysine lactate binding domains. The lysine lactate binding domains may be derived from the lysine lactate specific affinity reagent of the present invention.
[0066] In some embodiments, a lysine lactate acylation site in the peptide is not lactate acylated, and the lysine lactate acylation binding domain specifically binds to the lysine lactate acylation site in the peptide when the site is lactate acylated, but does not bind when the site is not lactate acylated.
[0067] In other embodiments, a lysine lactate acylation site in the peptide is lactate acylated, and the lysine lactate acylation binding domain specifically binds to the lysine lactate acylation site in the peptide when the site is not lactate acylated, but does not bind when the site is lactate acylated.
[0068] The lysine lactic acid acylation site can be combined with a lysine lactic acid acylation binding domain having a linker molecule. The linker molecule can be a peptide having any amino acid sequence and can have about 1-50 amino acids, preferably 1-30 amino acids, and more preferably 2-15 amino acids. In some embodiments, the linker molecule can be -Gly-Gly-. Regardless of whether the lysine lactic acid acylation site in the fusion protein reporter gene is lactic acid acylated or combined with a lysine lactic acid acylation binding domain, the length and content of the linker molecule can be adjusted to optimize the potential fluorescence resonance energy transfer (FRET) between the donor fluorescent moiety and the acceptor fluorescent moiety.
[0069] The fusion protein reporter gene may further comprise a targeting polypeptide. The targeting polypeptide may be selected from the group consisting of a receptor ligand, a nuclear localization sequence (NLS), a nuclear export signal (NES), a plasma membrane targeting signal, a histone binding protein and a nuclear protein.
[0070] A method for determining the level of protein lysine lactic acid acylation in a sample. The method includes detecting lactic acid acylated lysine in the sample, and also includes (a) contacting the sample with the fusion protein reporter gene of the present invention, and (b) comparing the fluorescence resonance energy transfer (FRET) level of the donor fluorescent part and the acceptor fluorescent part before and after the contact. The FRET level indicates the level of protein lysine lactic acid acylation in the sample. After the contact, the FRET level may increase or decrease.
[0071] The present invention also provides a method for determining the level of de-lysine lactylation of proteins in a sample. The method comprises (a) contacting the sample with the fusion protein reporter gene of the present invention, and (b) comparing the level of fluorescence resonance energy transfer (FRET) after the donor fluorescent moiety is contacted with the acceptor fluorescent moiety with the level of fluorescence resonance energy transfer (FRET) before contact. The level of FRET indicates the level of de-lysine lactylation of proteins in the sample. After contact, the FRET level may increase or decrease.
[0072] For the determination method in the present invention, the sample can be a biological sample (such as a body fluid or serum). The biological sample may include cells, tissue biopsies or clinical body fluids, and the source thereof may be obtained from a subject (e.g., a mouse, a rat or a human). The subject should be of normal health and may suffer from or may be prone to suffering from a disease related to protein lysine lactylation or de-lysine lactylation, which may be any disease or condition related to abnormal regulation of protein lysine lactylation or de-lysine lactylation, respectively. Examples of such disorders or diseases may include cancer, neurodegenerative diseases, aging, metabolic disorders and dysplasia.
[0073] The assay method of the present invention may also include comparing the FRET level in the sample with a control FRET level. The control FRET level may be the FRET level in a control sample obtained from a healthy subject or a subject not suffering from or susceptible to a lysine lactylation-related disease. The FRET level in the sample may be higher or lower than the control FRET level.
[0074] The assay method of the present invention may also include adding a reagent to the sample. In some embodiments, it can be concluded that the reagent can promote or inhibit protein lysine lactic acid acylation. In some other embodiments, the reagent is a screening candidate for a protein lysine lactic acid acylation regulator. The screening candidate can be a compound or a biomolecule.
[0075] Each assay method in the present invention provides a kit. The kit comprises the fusion protein of the present invention. The kit may also include instructions for instructing how to perform the method.
[0076] The present invention also provides a kit for separating peptides containing lactic acid acylated lysine. The kit comprises a separated lysine lactic acid acylation specific affinity reagent, which can specifically bind to the peptides containing lactic acid acylated lysine.
[0077] The present invention provides a method for treating or preventing a subject suffering from a disease related to protein lysine lactic acid acylation as needed. The method comprises providing a composition comprising an effective amount of a reagent for regulating protein lysine lactic acid acylation to the subject. The reagent may be a screening candidate validated by the determination method of the present invention. Protein lysine lactic acid acylation may be histone lysine lactic acid acylation.
[0078] The present invention provides a method for treating or preventing a subject suffering from a disease related to protein or de-lysine lactic acid acylation as needed. The method comprises providing a composition comprising an effective amount of an agent for regulating protein de-lysine lactic acid acylation to the subject. The agent may be a screening candidate validated by the determination method of the present invention. Protein de-lysine lactic acid acylation may be histone de-lysine lactic acid acylation.
[0079] Here, the term "about" when referring to a measurable value such as an amount, percentage, etc., is intended to include variations of ±20% or ±10%, preferably ±5%, even better ±1%, and even better ±0.1% of a specified value, depending on the circumstances.
[0080] Example 1. Metabolic regulation of gene expression by histone lactic acid acylation
[0081] Inspired by the discovery of various histone acylations derived from cellular metabolites, the researchers predicted and identified lysine lactate acylation (Kla) as a novel histone mark that can be stimulated by lactate (e.g. Figure 1 Initial evidence for this conclusion came from the observation of a mass shift of 72.021 Daltons for lysine residues in three proteolytic peptides detected in high performance liquid chromatography (HPLC)-mass spectrometry (MS / MS) analysis of trypsin-digested core histones from MCF-7 cells ( Figure 1 b) This mass shift is identical to the addition of a lactic acid group to the epsilon amino group of a lysine residue.
[0082] To verify the presence of lysine lactylation in histones, the researchers used four orthogonal methods. In the first two methods, the researchers compared HPLC-MS / MS with a synthetic peptide and its in vivo-derived counterpart to determine whether the two versions of the peptide had the same chemical properties in terms of chromatographic elution in HPLC and fragmentation spectra in MS / MS. To this end, the researchers prepared three histone peptides with Kla modifications: H3K23 QLATKlaAAR (sequence number 85), H2BK5PELAKlaSAPAPK (sequence number 86), and H4K8 GGKlaGLGK (sequence number 87). Each pair of peptides co-eluted in HPLC and had comparable MS / MS spectra ( Figure 1 b). To further confirm this modification, the researchers developed a pan-anti-Kla antibody. Immunoblotting using the pan-anti-Kla antibody confirmed the presence of histone Kla and showed that histone Kla levels increased in a dose-dependent manner under the action of exogenous L-lactic acid. Subsequently, mass spectrometry analysis identified 26 and 16 histone Kla sites from human MCF-7 cells and mouse bone marrow-derived macrophages (BMDM), respectively ( Figure 1 c). Finally, using the isotope L-lactate ( 13 C3) Metabolic labeling experiments followed by MS / MS analysis demonstrated that lysine lactic acid acylation can be derived from lactate. In summary, these experiments demonstrate that histone Kla is an in vivo protein post-translational modification derived from lactate.
[0083] Given that extracellular lactate can stimulate histone Kla, the researchers hypothesized that intracellular lactate production would also affect histone Kla levels. The researchers exposed MCF-7 and other cell lines to varying concentrations of glucose, the main source of intracellular lactate. The results showed that glucose induced lactate production and histone Kla levels in a dose-dependent manner ( Figure 2a, b). In contrast, 2-deoxy-D-glucose (2-DG), a non-metabolizable glucose analog, reduced lactate production and histone Kla levels ( Figure 2 d). In addition, metabolic labeling experiments using isotopic glucose (U-13C6) and MS / MS analysis showed that lysine lactate acylation was endogenously derived from glucose. Quantitative proteomic analysis showed that histones Kla and Kac have different 13 C Glucose incorporation dynamics. 13 C-labeled histone Kac reached a steady state at 6 h, which is similar to the observations of Liu et al. in HCT116 cells (Cell 175, 502-513E513, doi:10.1016 / j.cell.2018.08.040(2018). In contrast, histone Kla increased within 24 h. Immunoblotting results confirmed the MS / MS data of MCF-7 and other cell lines.
[0084] Lactate production depends on the balance between glycolysis and mitochondrial metabolism. The researchers tested whether the activity of enzymes in these two pathways could regulate lactate levels, which in turn could regulate the expression of histone Kla (such as Figure 2 e). Sodium dichloroacetate (DCA) and oxamate were used to inhibit lactate production by regulating the activities of pyruvate dehydrogenase (PDH) and lactate dehydrogenase (LDH), respectively. As expected, these two compounds reduced intracellular lactate levels ( Figure 2 f) and histone Kla levels ( Figure 2 g, h). In contrast, rotenone, an inhibitor of mitochondrial respiratory chain complex I, drives cells toward glycolysis, thereby increasing intracellular lactate and histone Kla levels ( Figure 2 f, i). Quantification of histone Kla and Kac labeling by stable isotope labeling with amino acids in cell culture (SILAC) and MS / MS analysis confirmed the immunoblot data for DCA- and rotenone-treated MCF-7 cells. 13 C6 glucose labeling experiments showed that DCA inhibited 13 Together, these observations suggest that endogenous lactate production is a key determinant of histone Kla levels.
[0085] Increased glycolysis and lactate production are associated with a variety of cellular processes. To investigate whether histone Kla is regulated by glycolysis under physiological conditions, the researchers chose two model systems: hypoxia and M1 macrophage polarization. In response to hypoxia, cells reprogram their metabolism by inhibiting oxidative phosphorylation and enhancing glycolysis, stimulating lactate production. Hypoxia induces lactate production and increases histone Kla levels in MCF-7 cells, but does not increase Kac levels ( Figure 2 j, k). SILAC-based mass spectrometry quantification of histone Kla and Kac confirmed the immunoblot data. Similar results were obtained in HeLa and RAW264.7 cells. In addition, the researchers found that LDH inhibitors (oxamate) or PDK1 inhibitors (DCA) attenuated the production of lactate and histone Kla induced by hypoxia. Under normoxic conditions, deletion of LDHA and LDHB completely inhibited the production of lactate and histone Kla in HepG2 cells. Hypoxic conditions could not be tested due to poor cell viability.
[0086] Emerging evidence shows that lactate has regulatory functions in both innate and adaptive immune cells and induces dramatic changes in gene expression, suggesting that lactate is more than a "waste product" of glycolysis. Pro-inflammatory M1 macrophages undergo metabolic reprogramming toward aerobic glycolysis to produce lactate, whereas anti-inflammatory M2 macrophages trigger a metabolic program of increased oxidative phosphorylation and fatty acid oxidation. Thus, our findings on histone Kla marks and their dynamics suggest a role for regulating gene expression during M1 macrophage polarization.
[0087] To test this hypothesis, the researchers examined the dynamic changes in lactate production and histone Kla marking during M1 macrophage polarization after treatment of BMDMs with lipopolysaccharide (LPS) and interferon-γ (IFNγ). The researchers observed elevated intracellular lactate levels within 16 to 24 hours after M1 activation ( Figure 3 a), which is closely related to the increase in histone Kla levels ( Figure 3 b, c). In contrast, histone Kac levels decreased at these time points ( Figure 3 b, c). This difference pattern yields U- 13 C6 glucose labeling experiments confirmed that 13 C-labeled histone Kac reached a peak 3 h after labeling and then decreased to a stable state, while histone Kla increased within 24 h. In addition, the LDHA-specific inhibitor GNE-140 inhibited the expression of histone Kla. 13C incorporation, but not Kac incorporation. Since replenishing cells with fresh medium every 4 h did not affect Kla levels, it can be concluded that the increase in histone Kla during M1 polarization is endogenous and not due to paracrine influences. The increase in lactate production and histone Kla is also specific to M1 macrophages, as they were not observed in M2 polarized BMDMs ( Figure 3 d), while the latter is more dependent on fatty acid oxidation.
[0088] Histone modification plays an important role in the regulation of gene expression. To investigate histone Kla-related genes after 24 h of macrophage M1 polarization, RNA-seq and binding site analysis were performed using anti-H3K18la or anti-H3K18ac antibodies, and their specificity was verified by dot blot, ChIP-qPCR analysis, and immunoblotting.
[0089] The researchers' binding site analysis data showed that both H3K18la and H3K18ac were enriched in the promoter region (±2kb of the transcription start site), and the mRNA level was stable. In addition, H3K18la increased (increased 2-fold) marked more genes than H3K18la decreased (decreased 2-fold), while H3K18ac modification had the opposite effect ( Figure 3 e). In addition, most of the genes with elevated H3K18la were specific, as 68% (1223 / 1787) of these genes did not show significantly elevated H3K18ac ( Figure 3 e, f). In contrast, no H3K18ac-specific genes were found ( Figure 3 e, f).
[0090] To investigate the correlation between H3K18la marks and gene expression, the researchers performed RNA-seq at 0, 4, 8, 16, and 24 hours after LPS / IFNγ challenge. As expected, inflammatory response genes such as Nos2 were induced 4 hours after LPS / IFNγ challenge, while their expression levels steadily decreased ( Figure 3 g). Interestingly, 1223 genes specifically marked by H3K18la elevation were more likely to be activated or reactivated at later time points (16 or 24 h) after M1 polarization ( Figure 3 h), which was closely associated with the induction of intracellular lactate and histone Kla levels at later time points ( Figure 3 ac). Gene ontology (GO) analysis showed that these H3K18la-specific genes were enriched in biological pathways independent of inflammation. One of the enriched pathways was wound healing (e.g. Arg1), which is associated with an M2-like phenotype ( Figure 3h). To confirm these findings with more physiologically relevant stimuli, the researchers stimulated M1 polarization with live or dead Gram-negative bacteria (Escherichia coli, Acinetobacter baumannii, and Pseudomonas aeruginosa). Similar to LPS, the bacteria induced lactate production and global histone Kla, but not histone Kac levels ( Figure 3 i), while the dynamics of early cytokine and late Arg1 expression remain unchanged ( Figure 3 j).
[0091] Arginine metabolism is a key catabolic and anabolic process during macrophage polarization. M1 macrophages are thought to have low ARG1 and can metabolize arginine to produce nitric oxide via nitric oxide synthase to kill pathogens, whereas M2 macrophages have high ARG1, which can produce ornithine to promote wound healing. ARG1 protein levels and activity are consistent with their RNA dynamics and increase significantly after 24-48 hours of M1 polarization, while NOS2 protein levels and function peak after 12 hours of M1 polarization and decline at subsequent time points ( Figure 3 k). Collectively, these findings suggest that induction of lactate during M1 activation at a late stage may generate a more stable phenotype that shares some similarities with the M2-like phenotype. Indeed, previous studies have shown that treatment of BMDMs with tumor cell-derived lactate can drive M2-like phenotypic features in tumor-associated macrophages (TAMs). In mouse tumor models, the researchers observed that Arg1 expression was positively correlated with histone Kla levels, but not with histone Kac levels, in TAMs isolated from B16F10 melanoma and LLC1 lung cancer.
[0092] Changes in gene expression during M1 polarization are caused by complex LPS / IFNγ-induced signaling, which includes the induction of lactate and histone Kla. To confirm the role of lactate and histone Kla in the regulation of gene expression, the researchers manipulated lactate levels during M1 polarization and examined its effects on the expression of Arg1, an M2-like gene. The researchers first deleted Ldha (LysM-Cre + / - Ldha fl / fl ) to reduce lactate levels. During M1 polarization, macrophages lacking LDHA have reduced lactate production and global histone Kla levels ( Figure 4 a, b). Although Ldha deletion in macrophages did not alter the expression of proinflammatory cytokines, it attenuated Arg1 and reduced histone Kla marks at the Arg1 promoter ( Figure 4c, d). Similar results were obtained when macrophages were polarized to M1 in the presence of glycolysis inhibitors (2-DG, DCA, and GNE-140). Next, the researchers increased lactate levels by treating M1 macrophages with exogenous lactate. Exogenous lactate increased intracellular lactate ( Figure 4 e) and histone Kla levels ( Figure 4 f), and induces Arg1 expression from the Arg1 promoter ( Figure 4 g) and Kla levels ( Figure 4 h). In contrast, exogenous lactate did not affect the expression of early pro-inflammatory genes. Moreover, exogenous lactate enhanced the expression of other M2-like genes, such as Vegfa, during M1 polarization. Thus, this data confirms that lactate and histone Kla have a positive role in driving the expression of M2-like genes during M1 macrophage polarization.
[0093] The correlation observed by the researchers between lactate, H3K18la, and M2 class gene expression does not necessarily mean that the histone Kla mark is a causative factor. Previous studies have shown that exogenous lactate can alter the expression of Arg1 and Vegfa in unstimulated (M0) macrophages through HIF1a. However, during M1 polarization, HIF1a regulation of Arg1 and Vegfa is not essential because the HIF1a protein is induced at early time points, resulting in HIF1a binding to the promoters of glycolytic genes instead of Arg1 and Vegfa.
[0094] To test whether histone Kla plays a direct role in transcriptional regulation, the researchers used a cell-free reconstituted chromatin-templated histone modification and transcriptional analysis approach that has been previously used to demonstrate direct transcriptional activation of p53- and p300-dependent histone Kac. In this assay, acetyl-CoA was replaced with L-lactyl-CoA (confirmed by HPLC and MS), which demonstrated the activity of p53-dependent, p300-mediated lactic acid acylation of H3 and H4 and the corresponding transcriptional effects. This effect was similar to that of acetyl-CoA-dependent histone acetylation and transcription. To confirm that transcription was directly mediated by lactic acid acylation of histones and not other proteins in nuclear extracts, reconstituted chromatin was reconstituted with core histones with lysine (K) to arginine (R) mutations in the histone tails. Compared with wild-type histones, H3 and H4 mutations abolished p300- and p53-dependent transcription, while H2A or H2B mutations did not. Taken together, these findings suggest that histone lactacylation, like histone acetylation, can directly promote gene transcription under the conditions described. To test the potential activity of p300 as a histone Kla writer in cells, the researchers overexpressed p300 in HEK293T cells and observed a slight increase in histone Kla levels. Conversely, the loss of p300 in HCT116 and HEK293T cells reduced histone Kla levels. Although the researchers cannot rule out an indirect role of p300 in these cells, combined with the in vitro enzymatic results, these data suggest that p300 is a potential histone Kla writer.
[0095] In response to bacterial infection, macrophages must respond quickly, producing large amounts of proinflammatory cytokines to help kill bacteria and recruit more immune cells to the site of infection. During this process, macrophages switch to aerobic glycolysis to support the expression of proinflammatory cytokines during M1 activation and produce the Warburg effect. Over time, this metabolic switch also increases intracellular lactate. The researchers found that after 16-24 hours of exposure to M1 polarizing stimuli, it also stimulated histone lysine lactic acid acylation. Proinflammatory genes do not require the induction or suppression of histone lactosylation. Instead, it can serve as a mechanism to initiate the expression of homeostatic genes traditionally associated with M2-like macrophages. The results of this study support a model in which the conversion to aerobic glycolysis that occurs during M1 polarization initiates a "lactate timer" that uses epigenetic mechanisms to induce M2-like features at a later stage, perhaps to help repair collateral damage incurred by the host during infection.
[0096] High levels of lactate (e.g., 40 mM in certain types of tumor tissue) are also associated with cardinal features of cancer and other diseases. Given that Kla modification can be stimulated by lactate and contributes to gene expression, Kla modification has the potential to fill an important knowledge gap in researchers' understanding of various physiological and pathological processes closely associated with lactate (e.g., infection, cancer).
[0097] method
[0098] Material.
[0099] Pan anti-Kac (PTM-101), pan anti-Kla (PTM-1401), anti-H3K18la (PTM-1406), anti-H4K5la (PTM-1407), and anti-H4K8la (PTM-1405) antibodies were prepared by PTMBio (Chicago, IL); anti-histone H3 (ab12079), anti-H3K18ac (ab1191), and anti-H3K27ac (ab4729) antibodies were purchased from Abcam (Cambridge, MA); and obtained from ActiveMotif (Carlsbad, CA). Drosophila spike-in antibodies (61686) and spike-in chromatin (53083); anti-LDHA (2012S) antibody from Cell Signaling Technology (Danvers, MA); anti-□-tubulin (05-829) and anti-LDHB (ABC927) antibodies from MilliporeSigma (Burlington, MA); anti-HIF-1a (NB100-105) antibody from Novus Biologicals (Littleton, CO); anti- iNOS (GTX130246) and anti-Arg1 (GTX109242) antibodies were purchased from GeneTex (Irvine, CA); anti-p300 (sc-584) was from Santa Cruz Biotechnology (Dallas, TX); anti-CD11b monoclonal antibody (M1 / 70), PE-cyano 7 (25-0112-82) and anti-F4 / 80 monoclonal antibody (BM8), APC (17-4801-82) were from Thermo Fisher Scientific (Waltham, MA) ; Lipopolysaccharide of Escherichia coli O111: B4 (L4391), sodium L-lactate (71718), L-(+)-lactic acid (L6402), sodium dichloroacetate (347795), cobalt chloride hexahydrate (C8661), rotenone (R8875) and acetyl-CoA (A2056) were purchased from Sigma-Aldrich (St. Louis, MO); sodium L-lactate (13C3, 98%) (CLM-1579-PK) and D-glucose (U-13C6, 99%) (CLM-1396-1) were purchased from Cambridge Isotope Laboratories (Andover, MA).Recombinant mouse IFN-γ protein (485-MI-100) was from R&D Systems (Bergisch-Gladbach, Germany); mouse interleukin-4 (130-097-760) was from Miltenyi Biotec (Bergisch-Gladbach, Germany); modified sequencing-grade trypsin was from Promega (Madison, WI); lactate colorimetric assay kit II (K627-100), arginase activity colorimetric assay kit (K755-100), and nitric oxide synthase (NOS) activity assay kit (K205-100) were purchased from Biovision, Inc (Milpitas, CA).
[0100] Cell culture.
[0101] MCF-7, MDA-MB-231, HeLa, A549, HepG2, MEF, and RAW 264.7 cells were obtained from the American Type Culture Collection and cultured in Dulbecco's modified Eagle's medium supplemented with 10% FBS and 1% glutamine (GIBCO, Gaithersburg, MD). Cells were routinely tested for mycoplasma contamination (MP0035, Sigma-Aldrich, St. Louis, MO), and only negative cells were used in the experiments. No specific cell line validation was performed. For growth of cells under hypoxic conditions, they were performed in a dedicated, humidified chamber and equilibrated with 1% oxygen / 94% nitrogen / 5% carbon dioxide for the specified time.
[0102] Mouse experiments.
[0103] All animal use and experiments were approved by the University of Chicago Institutional Animal Care and Use Committee (ACUP#72209). fl / fl The mice (Jackson Laboratory, 030112) and LysMcre mice (Jackson Laboratory, 004781) were used to breed LysMcre + / - Ldha fl / fl and littermate control LysMcre- / -Ldhafl / fl mice. The following primers were used for genotyping: Ldha forward:
[0104] CTGAGCACCCATGTGAGA (SEQ ID NO: 88) and Ldha reverse: AGCAACTCCAAGTGGA (SEQ ID NO: 89). LysMcre: CCCAGAAAATGCCAGATTACG (SEQ ID NO: 90), LysM normal: CTTGGGCTGCCAGAATTTCC (SEQ ID NO: 91) and
[0105] LysMWT:TTACAGTCGGCCAGCTGAC (SEQ ID NO: 92). Macrophages were derived from the bone marrow of 8-week-old male C57BL / 6 mice. BMDM cells were stimulated with 5 ng / ml LPS and 12 ng / ml IFNγ or 20 ng / ml interleukin 4 to produce M1 or M2 phenotypes for 24 hours or the indicated time. BMDM cells were infected with bacteria. Escherichia coli, Acinetobacter baumannii, or Pseudomonas aeruginosa were cultured overnight and diluted in RPMI-1640 and added to BMDM cells in 6-well plates at 2-fold and 20-fold infection rates. Control plates were infected with paraformaldehyde-inactivated bacteria or treated with 5 ng / mL lipopolysaccharide (LPS) in the absence of bacteria. The plates were centrifuged at 2170 rpm for 30 minutes to promote infection, and then incubated in a humidified incubator at 37 degrees Celsius under 5% carbon dioxide for 30 minutes. To kill extracellular bacteria, the medium on the confluent cell monolayer was replaced with fresh medium containing 100 μg / mL gentamicin and the culture was continued for 1 h. After the culture, the medium from the infected cells was removed and replaced with fresh medium containing 25 μg / mL gentamicin. For consistency, LPS-treated cells and cells infected with dead bacteria were also treated with gentamicin. Cells were cultured for 24 h before lysis. BMDM cells were randomly but not blindly assigned to different treatment groups.
[0106] Tumor inoculation and isolation of tumor-associated macrophages.
[0107] LLC1 cells (0.5×106) or B16F10 cells (1×106) were injected into 7-week-old C57BL / 6 mice (Jackson Laboratory). When the tumor reached about 600mm3, the mice were killed for tumor isolation. The tumor was shaken at 200 rpm for 30 minutes at 1% BSA / PBS and 37°C with collagenase type 4 (Worthington, 3mg / mL) and hyaluronidase (Sigma, 1.5mg / mL). The digested tumor was then filtered through a 70μm cell strainer, followed by an RBC lysis step and passed through another 40μm filter. The cells were resuspended in separation buffer (0.1% BSA / PBS, 2mMEDTA), layered onto FicollPaqueTMPLUS (GE Healthcare), and centrifuged at 450g for 30 minutes without breaking them. The middle white blood cell layer was taken to obtain mononuclear immune cells. CD11b microspheres (Mitenyi Biotec) were then used to separate TAMs according to company instructions. The purity of TAMs was determined by flow cytometry using CD11b and F4 / 80 antibodies. The data were quantified using FlowJov.10.4.1.
[0108] Peptide immunoprecipitation.
[0109] Histones were extracted from human MCF-7 or mouse BMDM cells using a standard acid extraction protocol (Shechter et al, Nat Protoc 2, 1445-1457, doi: 10.1038 / nprot.2007.202 (2007)) and trypsin digested according to the manufacturer's instructions. Pan-anti-Kla or pan-anti-Kac antibodies were first bound to NESA Sepharose beads (GE Healthcare BioSciences, Pittsburgh, PA) and then incubated with trypsin-digested histone peptides at 4°C with gentle agitation overnight. The beads were then washed three times with NETN buffer (50 mM Tris-Cl pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5% NP-40) and washed with ETN buffer (50 mM Tris-Cl pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5% NP-40). The beads were washed twice with 1% 4% TFA (8.0, 100 mM NaCl, 1 mM EDTA) and once with water. The peptides were eluted from the beads with 0.1% TFA and dried in a SpeedVac system (ThermoFisherScientific, Waltham, MA).
[0110] HPLC / MS / MS analysis.
[0111] The peptide samples were loaded onto a homemade capillary column (10 cm length x 75 mm ID, 3 μm particle size, Dr. Maisch GmbH, Ammerbuch, Germany) connected to an EASY-nLC 1000 system (Thermo Fisher Scientific, Waltham, MA). The peptides were separated and eluted with a gradient from 2% to 90% HPLC buffer B (0.1% formic acid in acetonitrile, v / v) in buffer A (0.1% formic acid in water, v / v) at a flow rate of 200 nL / min for 60 min (34 min for co-solubility studies). The eluted peptides were then ionized and analyzed by a Q-Exactive mass spectrometer (Thermo Fisher Scientific, Waltham, MA). Full mass spectra were acquired in an Orbitrap mass analyzer in the range of m / z 300-1400 with a resolution of 70,000 at m / z 200 in the primary spectrum. The 12 most intensely charged ions were fragmented ≥2 times with a normalized collision energy set to 27 and a secondary spectrum with a resolution of 17,500 at m / z 200 was acquired.
[0112] Isotope labeling experiments.
[0113] MCF-7 cells were cultured in DMEM high glucose medium and 10% FBS. Cells were labeled with isotope lactate and 10 mM 13 C3L-sodium lactate was used to treat the cells for 24 hours. To label the cells with isotopic glucose, the cells were switched to DMEM glucose-free medium (Gibco) for 24 hours, then supplemented with 25 mMU-13C6 D-glucose and cultured for three more generations. Histones were extracted, digested with trypsin, immunoprecipitated with pan-anti-Kla antibodies, and analyzed by HPLC / MS / MS as described above.
[0114] SILAC-based quantification.
[0115] MCF-7 cells need to be in the presence of heavy isotopes (L-lysine- 13 C6, 15 N2) or "light isotopes" (L-lysine- 12 C6, 14 N2) Cultured in DMEM for more than 6 generations and supplemented with 10% dialyzed FBS
[0116] (SerumSource International, Charlotte, North Carolina) to achieve a labeling efficiency of more than 99%. "Heavy isotope" labeled cells and "light isotope" labeled cells were mixed in a 1:1 ratio. Histones were extracted, digested with trypsin, immunoprecipitated with pan anti-Kla antibody, and analyzed by HPLC / MS / MS as described above. Quantification was performed using Maxquant20. The H / L ratios obtained from Maxquant were normalized by protein abundance.
[0117] Synthesis of L-lactate-CoA.
[0118] L-lactic acid (90mg, 1mmol) is dissolved in 5mL freshly distilled CH2Cl2.N-hydroxysuccinimide (115mg, 1mmol) is added to the solution, and the reaction mixture is ultrasonically treated to obtain a clear solution.N, N'-dicyclohexylcarbodiimide (DCC, 227mg, 1.1mmol) is then added in one portion. The white precipitate formed during addition.The reaction mixture is stirred at room temperature and overnight.Then the white precipitate is filtered and washed with CH3CN.Then the obtained organic solvent is evaporated in vacuo to obtain a crude product L-lactic acid-NHS (170mg, 91% yield), which can be used directly in the next step without further purification.0.0065mmol hydrated coenzyme A (5mg) is dissolved in 1.5mL 0.5MNaHCO3 (pH 8.0) and cooled under an ice bath. Then L-lactic acid-NHS (2.5 mg, 0.013 mmol) in 0.5 mL CH3CN / acetone (1:1 v / v) was added dropwise to the CoA solution. The reaction solution was stirred at 4 ° C overnight, and then the pH was adjusted to 4.0 with 1.0 M HCl to quench it. The reaction mixture was purified with a 5-45% buffer A in buffer B at a flow rate gradient of 5 ml / min for 30 minutes; the UV detection wavelengths were fixed at 214 and 254 nm (HPLC buffer A: 0.05% TFA in water; HPLC buffer B: 0.05% TFA in acetonitrile). The components were collected, frozen with liquid nitrogen and then lyophilized. m = 2 mg, yield 38% 1 H NMR (400 MHz, deuterium oxide) δ 8.57 (s, 1H), 8.33 (s, 1H), 6.12 (d, J = 5.7 Hz, 1H), 4.49 (s, 1H), 4.29–4.24 (m, 1H), 4.14 (s, 2H), 3.93 (s, 1H), 3.75 (d, J = 8.6 Hz, 1H), 3.48 ( d, J = 7.6 Hz, 1H), 3.35 (t, J = 6.4 Hz, 2H), 3.22 (d, J = 5.2 Hz, 3H), 2.89 (q, J = 6.2 Hz, 2H), 2.32 (t, J = 6.4 Hz, 2H), 1.23 (d, J = 6.9 Hz, 3H), 0.83 (s, 3H), 0.70 (s, 3H). MALDI m / z calculated for C24H41N7O18P3S+ [M+H]+: 840.1, found 839.6.
[0119] In vitro chromatin template-based analysis of histone modifications and transcription.
[0120] Purification of recombinant proteins and chromatin assembly were performed as described previously (Tang et al., Cell 154297-310, doi:10.1016 / j.cell.2013.06.027(2013)). Chromatin template histone modification and transcriptional analysis were as described previously (Tang et al., Cell 154297-310, doi:10.1016 / j.cell.2013.06.027(2013)), except that lactate-CoA was used instead of acetyl L-CoA and [α-32P]CTP was used instead of [α-32P]-UTP. H3KR, H4KR, H2AKR, and H2BKR histone mutants were the same as previously described (Tang et al., Cell 154297-310, doi:10.1016 / j.cell.2013.06.027(2013)). Histone modifications were monitored by immunoblotting, and transcripts were monitored by autoradiography (Tang et al., Cell 154:297-310, doi:10.1016 / j.cell.2013.06.027(2013)).
[0121] RNA-seq.
[0122] Total RNA was extracted from activated BMDM cells using RNeasy Plus micro kit (74134, Qiagen, Hilden, Germany). Libraries were prepared using 2-4 μg of total RNA as starting material, and Illumina TruSeq Stranded mRNA Library Preparation Kit Set A (RS-122-2101, Illumina, San Diego, CA). The size of these libraries was selected using Agencourt AMPure XP beads (A63882, Beckman Coulter, Brea, CA), with an average size of 400 bp. The libraries were sequenced using Illumina HiSeq 4000 (double-end sequencing 50 bp).
[0123] Bioinformatics analysis of RNA-seq data: Sequencing quality was assessed using FastQC version 0.11.4. All fragments were mapped to the reference genome of IlluminaiGenomesUCSCmm10 using HISAT2 version 2.1.0. After retaining only genes with cpm greater than one-quarter of the samples and standardizing the sample library size using the TMM method of the edgeR software package, differential expression analysis was performed using edgeR version 3.16.5. Perseus version 1.6.1.1 was used for hierarchical clustering and heat maps were generated (http: / / www.coxdocs.org / doku.php?id=perseus:start). Log2-converted gene expression values (fragments per kilobase transcribed, fragments per million sequenced (RPKM)) were normalized by subtracting the mean of each row and hierarchical clustering was performed using the Pearson correlation algorithm. Gene ontology analysis was performed using DAVIDBioinformaticsResources6.8.
[0124] The following primers were used for RT-qPCR analysis: Arg1: ctccaagcaaggttagag (SEQ ID NO: 93), aggctgtcattaggacatc (SEQ ID NO: 94); Vegfa: CCACGAGAGGAGAGAGAGTCC (SEQ ID NO: 95), CGTTACAGAGCCTGCACGG (SEQ ID NO: 96);
[0125] Il6: GTTCTGGGAAATCGTGGA (SEQ ID NO: 97), TTTCTGCAAGTGGCATCG (SEQ ID NO: 98); Il1b: TTTGAGAGAGAGAATGACC (SEQ ID NO: 99), CTCTTGTTGATGTGCTGCTG (SEQ ID NO: 100);
[0126] Ifnb1: CAGCTCCAGAAAGGACGAAC (sequence number: 101),
[0127] GGCAGTGTTAACTCTTCTGCAT (SEQ ID NO: 102);
[0128] Cxcl10:CCAAGTGCCGTCATTTC (serial number: 103),
[0129] GGCTCGCAGGGATGATTTCAA (SEQ ID NO: 104);
[0130] Tnfa: CCCTCACACTCAGATCTTCT (sequence number: 105), GCTACGACGTGGCTACAG (sequence number: 106).
[0131] ChIP-seq.
[0132] Cross-link-free immunoprecipitation was performed following published protocols (Cuddapahe et al., Cold Spring Harb Protoc 2009, pdbprot5237, doi:10.1101 / pdb.prot5237 (2009)), and spiked-in was added for normalization purposes. Spike-in was performed according to the supplier's protocol (#61686, Activemotif, Carlsbad, CA). Briefly, 50 ng of spike-in chromatin (#53083, Active Motif, Carlsbad, CA) was added to 25 μg of BMDM chromatin and 2 μg Spike-in antibody (#61686, Active Motif, Carlsbad, CA) and 4 μg of anti-H3K18la or anti-H3K18ac antibody were added. After incubation at 4°C for 4 hours, protein A Sepharose (17-5280-01, GE Healthcare Life Sciences, Pittsburgh, PA) was added and incubated for another 2 hours, and then washed with buffer TSEI (0.1% SDS, 1% TritonX-100, 2mM EDTA, 20mM Tris-HCl pH 8.0, 150mM NaCl), TSEII (0.1% SDS, 1% TritonX-100, 2mM EDTA, 20mM Tris-HCl pH 8.0, 500mM NaCl), buffer III (0.25M LiCl, 1% NP-40, 1% deoxycholate, 1mM EDTA, 10mM Tris-HCl pH 8.0, 500mM NaCl), and buffer III (0.25M LiCl, 1% NP-40, 1% deoxycholate, 1mM EDTA, 10mM Tris-HCl pH 8.0, 500mM NaCl). 8.0) and TE buffer (1mM EDTA, 10mM Tris-HCl pH 8.0) were washed sequentially. Finally, the chromatin DNA was eluted with a buffer containing 1% SDS and 0.1M N AHCO3. The eluate was digested with RNase A (12091021, Thermo Fisher Scientific, Waltham, MA) and proteinase K (AM2546, Thermo Fisher Scientific, Waltham, MA). DNA was recovered using a QIAquick PCR purification kit (#28106, Qiagen, Hilden, Germany) according to the manufacturer's instructions.
[0133] ChIP-seq libraries were constructed using the AccelNGS2S Plus DNA library kit (Swift Biosciences, Ann Arbor, MI) according to the manufacturer's instructions. The library was then amplified and fragment size assessed using a TapeStation (Agilent, Santa Clara, CA) and quantified using the Qubit ds DNA HS assay kit (Thermo Fisher Scientific, Waltham, MA). Index libraries were merged and sequenced using a 50-nt single-end sequencing configuration on a HiSeq 4000 sequencer (Illumina, Sandiego, CA).
[0134] Bioinformatics analysis of ChIP-seq data: Sequencing quality was assessed using FastQC version 0.11.4. All fragments were mapped to the reference genome of IlluminaiGenomesUCSCmm10 using Bowtie version 2.2.6, and only unique sequenced fragments were retained. The files were then converted to bam format, sorted, and duplicate PCRs were removed using SAMtools version 0.1.19. Peaks were called at q value = 0.01 using MACS version 2.2.1. To quantify and directly compare H3K18la or H3K18ac in different samples (M0 and M1 macrophages), the uniquely mapped H3K18la or H3K18ac fragments in the promoter region (2 kb around the transcription start site) of each gene were counted using featureCounts version 1.5.0-p1 and then normalized by the Spike-inChIP fragment counts of the corresponding condition (M0 or M1 macrophages). Overlapping genes in ChIP-seq and RNA-seq data were used for all subsequent analyses. Gene ontology analysis was performed using DAVID Bioinformatics Resources 6.8.
[0135] The following primers were used for qPCR analysis of gene promoter regions in human cells:
[0136] FOXO3a-promoter: CAGTGAGGTTG (SEQ ID NO: 107), AAAGCCTCTTTGCTT (SEQ ID NO: 108); FOXO3a-downstream: TGCACAGAGCCAGAAG (SEQ ID NO: 109), GCTCCCACAGAGACGTAA (SEQ ID NO: 110); LDHA promoter: TAAGGGGGGATACCTCT (SEQ ID NO: 111), CCCAAGAGAAAAATGCAAGC (SEQ ID NO: 112). The following primers were used for qPCR analysis of gene promoter regions in mouse cells: Arg1 / Arg1 PTM: AAGCTGGCCTCAGACAT (SEQ ID NO: 113), GGTAACCCGCTGGAAAGGAT (SEQ ID NO: 114);
[0137] Arg1-HRE-1kb:CCCGAGGTTTGACCCGAAGAAGAA (SEQ ID NO: 115),
[0138] CTTTACACAGGGGACCGGACC (sequence number: 116);
[0139] Arg1-HRE-2kb: TGTCTCAGTTCCA (SEQ ID NO: 117),
[0140] AGCAATTGGCATCTGATGGA (SEQ ID NO: 118);
[0141] Vegfa / VegfaPTM: CGAGCTAGCACTCTCCCAG (SEQ ID NO: 119),
[0142] AACTTCTGGGCTTCGC (SEQ ID NO: 120);
[0143] Vegfa-HRE-1kb: GGCACAATTTGTGCACT (SEQ ID NO: 121),
[0144] CTGCCAGACTACAGTGCA (SEQ ID NO: 122);
[0145] Vegfa-HRE-2kb: ACCTGATCTCTGCT (sequence number: 123), CAGCCTCTGTATGCGA (sequence number: 124); Vegfa-HRE-3kb: GCAGAACCTAGGCTTCACGT (sequence number: 125), TTGAAGGGCTGACATGGCT (sequence number: 126); Eno1: AAGGTCAGCAAGGGTCGT (sequence number: 127), CGTACTCCGAGTCCACAG (sequence number: 128); Glut1 (Slc2a1): TAGATCCCTCCTTGCT (sequence number: 129), GAACACGTAGCTGCTCACA (sequence number: 130); Genedesert: CTGCCAGGTTGTAGAGAGAGGG (sequence number: 131), GCCAGATCATGGCTTGG (sequence number: 132).
[0146] Data analysis.
[0147] No statistical method was used to predetermine the sample size. GraphPadPrism 7.0 software was used to determine the significance of the experimental data differences. All numerical values related to statistics are presented as mean values and their standard errors. For data without statistical data, unless otherwise stated, the experiment was repeated at least three times to ensure its reproducibility. All documents, books, manuals, papers, patents, published patent applications, guidelines, abstracts and other references cited herein are incorporated herein by reference. Although the specification and practice of the present invention have been shown and described in this application, it is obvious to those skilled in the art that the intention of providing these embodiments is only as an example, and the appended claims are intended to define the true scope and spirit of the present invention.
Claims
1. Use of lactic acid acylated lysine in a peptide fragment for preparing an affinity reagent capable of specifically binding to lactic acid acylated lysine in a peptide.
2. The use according to claim 1, wherein The peptide fragments are derived from histones or fragments thereof.
3. The use according to claim 2, wherein the histones are derived from selected from humans, mice, Saccharomyces cerevisiae, Tetrahymena thermophila, Drosophila melanogaster and Caenorhabditis elegans.
4. The use according to any one of claims 1 to 3, wherein the peptide fragment comprises an amino acid sequence selected from sequence numbers 29 to 87, and the sequence must have a homology of more than 70% with the amino acid sequence.
5. The method according to any one of claims 1 to 3, wherein the amino acid sequence contained in the peptide fragment is selected from the group consisting of sequence numbers 29 to 87.
6. The use according to any one of claims 1 to 5, wherein the peptide fragment comprises at least one or two amino acid residues on both the N-terminal and C-terminal sides of the lactic acid acylated lysine.
7. The use according to any one of claims 1 to 6, wherein The binding of the affinity reagent to the peptide fragment depends on the surrounding peptide sequence of the lactylated lysine in the peptide.
8. The use according to any one of claims 1 to 7, wherein The affinity reagent is a protein.
9. The use according to any one of claims 1 to 8, wherein the affinity reagent is an antibody.
10. A method for detecting lactic acid acylated lysine in a protein or a peptide fragment thereof, comprising: (a) contacting the protein or its peptide fragment with an affinity reagent according to any one of claims 1 to 9, wherein the affinity reagent can specifically bind to lactic acid acylated lysine in the protein or its peptide fragment, thereby forming a binding complex of the protein or its peptide fragment and the affinity reagent, and (b) detecting the binding complex, wherein the presence or amount of the binding complex indicates the presence or amount of lactylated lysine in the protein or fragment thereof.
11. The method of claim 10, wherein the peptide is derived from a histone or a fragment thereof.
12. The method according to claim 11, wherein the histones are derived from selected from human, mouse, Saccharomyces cerevisiae, Tetrahymena thermophila, Drosophila melanogaster and Caenorhabditis elegans.
13. The method according to any one of claims 10-12, wherein the peptide comprises an amino acid sequence selected from SEQ ID NOs: 29-87, and the sequence must have a homology of more than 70% with the amino acid sequence.
14. A method according to any one of claims 10-12, wherein the amino acid sequence contained in the peptide is selected from the group consisting of sequence numbers: 29-87.
15. The method according to any one of claims 10 to 14, wherein the peptide comprises at least one or two amino acid residues on both the N-terminal and C-terminal sides of the lactylated lysine.
16. The method according to any one of claims 10 to 15, wherein the binding of the affinity reagent to the peptide is dependent on the surrounding peptide sequence of the lactylated lysine in the peptide.
17. The method according to any one of claims 10 to 16, wherein the affinity reagent is a protein.
18. The method according to any one of claims 10 to 17, wherein the affinity reagent is an antibody.
19. The method according to any one of claims 10 to 18, further comprising quantifying lactic acid acylated lysine in the protein or fragment thereof.
20. A method for separating the affinity reagent according to any one of claims 1 to 9, wherein the affinity reagent can specifically bind to lactic acid acylated lysine in a peptide, the method comprising: (a) exposing a protein library to a peptide containing lactacylated lysine, whereby proteins from the protein library can specifically bind to the lactacylated lysine and form a binding complex with the peptide; and (b) separating the protein from the binding complex, wherein the separated protein is the affinity reagent.
21. A method for separating an affinity reagent according to any one of claims 1 to 9, wherein the affinity reagent can specifically bind to lactic acid acylated lysine in a peptide, the method comprising: (a) immunizing a host with a peptide containing lactic acid acylated lysine, thereby causing it to produce antibodies; as well as (b) separating the antibody from the host, wherein the antibody thus separated is the affinity reagent.
22. The method according to claim 20 or 21, wherein the peptide comprises at least one or two amino acid residues on both the N-terminal and C-terminal sides of the lactacylated lysine.
23. The kit includes: (a) an affinity reagent as claimed in any one of claims 1 to 9, which can specifically bind to lactic acid acylated lysine in a peptide, and (b) The detection method according to any one of claims 10 to 19, comprising instructions for an affinity reagent for detecting lactic acid acylated lysine in a protein or a fragment thereof.
24. The kit includes: (a) a peptide comprising lactic acid acylated lysine, and (b) The separation method according to any one of claims 20 to 22, comprising instructions for separating an affinity reagent that specifically binds to lactylated lysine in a peptide.
25. A peptide comprising lactic acid acylated lysine.
26. The peptide according to claim 25, wherein the peptide is derived from a histone or a fragment thereof.
27. The peptide according to claim 26, wherein the histone is derived from a selected from human, mouse, Saccharomyces cerevisiae, Tetrahymena thermophila, Drosophila melanogaster and Caenorhabditis elegans.
28. The peptide according to any one of claims 25-27, wherein the peptide comprises an amino acid sequence selected from sequence numbers: 29-87, and the sequence must have a homology of more than 70% with the amino acid sequence.
29. A peptide according to any one of claims 25-27, wherein the amino acid sequence contained in the peptide is selected from the group consisting of sequence numbers: 29-87.
30. The peptide according to any one of claims 25 to 29, wherein the peptide comprises at least one or two amino acid residues on both the N-terminal and C-terminal sides of the lactacylated lysine.
